Temocapril
 | This article needs additional citations for verification. (January 2021) |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H28N2O5S2 |
| Molar mass | 476.61 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Temocapril (also known as temocaprilum [Latin]; brand name Acecol) is an ACE inhibitor. It was not approved for use in the US.
It is administered as inactive prodrug, then converted to its active metabolite, temocaprilat.[1]
It was patented in 1984 and approved for medical use in 1994.[2]
References
[edit]- ^ Yasunari, K., Maeda, K., Nakamura, M., Watanabe, T., Yoshikawa, J., & Asada, A. (2004). Pharmacological and clinical studies with temocapril, an angiotensin converting enzyme inhibitor that is excreted in the bile. Cardiovascular drug reviews, 22(3), 189–198. https://doi.org/10.1111/j.1527-3466.2004.tb00140.x
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 469. ISBN 9783527607495.
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
 | This stereochemistry article is a stub. You can help Wikipedia by expanding it. |